Dr. Amy C. Moore
@acmoorephd
Cancer advocate, scientist and KOL. Director, Patient Engagement & Advocacy at Summit Therapeutics (@SMMT_TX). Opinions expressed are my own.
Are you a Young Investigator working on EGFR-mutant lung cancer? ✨ Finalists present live, receive coaching, and connect with top experts and patient advocates. Apply by Aug 8 - ceconcepts.com/egfr-summit #EGFRSummit #LungCancerResearch
Such important discussion by @MdWistuba on when and how to test for biomarkers in #lungcancer at #ilcc2025. @gotoPER
Relevant to the presentation Dr. @StephenVLiu did for the @IASLC Academy this AM. How to leverage social media to combat misinformation for patients with #cancer.
To help stop cancer misinformation on social media, health care providers can participation in social networks to see the types of content to which their patients are exposed, disseminate evidence‐based information, and correct misinformation. acsjournals.onlinelibrary.wiley.com/doi/10.3322/ca… @LoebStacy
Behind every biomarker is a person. It was an honor to co-author this comprehensive review on optimizing treatment for #EGFRm #NSCLC. acsjournals.onlinelibrary.wiley.com/doi/full/10.33… It isn't easy for a patient/advocate to contribute meaningfully to long, technical articles, but that's exactly why…
We are learning from the best! @StephenVLiu on use of social media for thoracic oncology. #LCSM @IASLC Academy
Great presentation on Social Media use in our @IASLC Academy by @StephenVLiu ! Thanks for your contribution! Important insights! @RManochakian @LuisRaezMD @ElinardouHelena @acmoorephd
Available @JTOonline - the 2024 @IASLC Global Survey on Biomarker Testing. Majority (67%) reported most patients had biomarker testing (up from 39% in 2018) but 43% sometimes treated before results. Barriers: cost, time, tissue, access, awareness. jto.org/article/S1556-…
Science is no joke. But in the height of the pandemic, I apparently thought it was.
According to @wef, #LungCancer claims over 1.8 million lives annually, with low- & middle-income countries bearing a disproportionate burden due to limited access to #EarlyDetection & treatment. Learn more: tinyurl.com/4yxfzdaz
“Many Lung Cancers Are Now in Nonsmokers.” @nytimes tells the story of a shifting epidemic: lung cancer among people, mostly women — who’ve never smoked. The face of lung cancer is changing. 🔗 nytimes.com/2025/07/22/wel…
🔵🫁 ¿Eres #paciente de #cáncerdepulmón? En @AEACaP te damos 5⃣ razones por las que deberías asociarte👇 ➡️ ¿Qué te ofrecemos? ✅ Atención psicológica y 🛋️ ✅Resolución de consultas ✅ Asesoramiento jurídico ⚖️ ✅ Búsqueda de ensayos clínicos ✅ Unidades de ejercicio físico🏃♂️
Meet Aurora Lucas, patient advocate for the #EQUALStudy. At 28, she was denied scans despite serious symptoms, overlooked because she didn’t meet screening criteria. Her story drives our push for equity in lung cancer detection. #HealthEquity #LungCancerAwareness
🚨🔥Hot off the press. Just published @JCO_ASCO @ASCO Important paper on an important topic: ✅The use of Patient-Centered #Language in the Dissemination of #CancerResearch. 📝By an amazing #Scientist & #Patient-Partnered Working Group. 👇🏻 brnw.ch/21wUmvH
Huge thanks to @9NEWS & @KyleClark for shining a light on #LungCancer for #WorldLungCancerDay on 8/1/25! Amplifying our voices helps break stigma and brings #hope #anyone withlungscangetlungcancer #raiseyourribbons #ItsUp2Us youtube.com/watch?v=cc5vDV…
Update to the @ASCO Living Guidelines for NSCLC without a driver alteration @JCO_ASCO from @dwightowenmd et al includes discussion on ivonescimab, the PD-1 / VEGF bispecific antibody, and the HARMONi-2 trial. Promising results but awaiting more data. ascopubs.org/doi/10.1200/JC…
#ALK is a viable target even in squamous NSCLC, demonstrated by this case + review in @ClinicalLung. However, significant variability in quality of response. While most respond, many brief courses of crizotinib, one on 1L alectinib for 5y and counting. clinical-lung-cancer.com/article/S1525-…
Dr. @triparnasen reviews updates on biomarkers and the classification of SCLC. An important point noted here: SCLC subtypes are heterogenous AND plastic, further enhanced by treatment! #BTGLung2025
Tomorrow, I turn 50. In the past six months, I have lost both my father and my father-in-law. I have embarked on a new career. Through the sadness and fear, I find myself stronger than I thought and more sure of who I am than perhaps any point before.
The amazing @leahlphillips and YLCI is featured in this article on the front page of @nytimes ! So proud of you Leah - Let’s keep changing the face of lung cancer 🤍🤍🤍
Spending a few days with my mom and brother. Tonight’s sunset.
Whatever you want to know about #EGFR-addicted lung cancer, from the very beginning to today, you’ll find it in this masterpiece. It’s been a real privilege to collaborate on this project. @Maxime_Borgeaud @Timothee_MD @JairBar4 @kaushalpar @jillfeldman4 @LeXiuning @Alfdoc2
Activating mutations in EGFR gene has revolutionized management of #LungCancer, enabling development of TKIs. New review on strategies to optimize treatment: acsjournals.onlinelibrary.wiley.com/doi/full/10.33… @Alfdoc2 @Maxime_Borgeaud @Timothee_MD @JairBar4 @kaushalpar @jillfeldman4 @LeXiuning @OncoAlert